Philip Hemme, Author at Labiotech.eu

About

Young French-German Entrepreneur, Co-founder & CEO of Labiotech.eu. High-level table tennis player, and German beer/French Wine lover 🙂

Articles by Philip Hemme

News and Trends 12 Nov 2015

Interview: CureVac, the ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market

I am still at the mRNA Convention in Berlin…and was invited for a second interview – this time with the ‘RNA People’, battling to be the first to get an mRNA Drug onto the Worldwide Market. I had a chat with Franz-Werner Haas, the Chief Corporate Office of CureVac. We talked a lot about this […]

November 12, 2015 - 1 minutemin - By Philip Hemme

News and Trends 12 Nov 2015

EU’s Largest Private Biotech talking on the Future of mRNA Therapies

Today is the 3rd International mRNA Health Conference in Berlin. I jumped in the metro to go there and interview the most successful people of the field… We first interviewed Sean Marett, COO of BioNTech. This German Biotech is the largest private Biotech in EU and so far counts over 400 employees…BioNTech also recently signed […]

November 12, 2015 - 1 minutemin - By Philip Hemme

News and Trends 9 Nov 2015

A Group of French Medics are Questioning the Fastest-Growing Big Biotech in the World…

Approved drugs can always show bad signs once injected massively. Four physicians from Paris sent a letter to the New England Journal of Medicine to report that Gilead’s Hepatitis C blockbuster drug, Sovaldi, can cause abnormally slower heart rates and risks of Heart Failure… The French Physicians report used data based on 415 patients treated […]

November 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 9 Nov 2015

This French Biotech has a ‘Super-Insulin’ up its Diabetes Sleeve

Human insulin produced in Bacteria is already a miracle for Diabetes…but sometimes, it’s not as efficient as it could be. The French Biotech Adocia is developing a super-insulin and showed successful efficiency data in a early-stage human trials. Adocia is a Lyon-based Biotech we have discussed before. Even if its logo is a bit strange […]

November 9, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 9 Nov 2015

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

Cell-based Immune-oncology therapies continue to deliver amazing results. After Cellectis wondersaving from last week, Oxford’s Adaptimmune has some surprisingly good results too. Adaptimmune is a British, Oxford-based immuno-oncolgy company. It held a massive IPO last year, raising up to €150M on the NASDAQ, and its CEO was interviewed by BIO (video here) where he seemed […]

November 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Nov 2015

What Happened this Week? BIO-Europe 2015, mRNA deal, Cellectis CAR-T

Monday: The French Scientist Who Also ‘Discovered’ CRISPR is Finally Recognized with a Prize too Tuesday: €100 Million Investment Round Prepares CureVac For Vaccine Expansion Wednesday: €1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech Thursday: Damn, that was BIO-Europe 2015 in Munich! Friday: Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on […]

November 7, 2015 - 1 minutemin - By Philip Hemme

News and Trends 5 Nov 2015

Damn, that was BIO-Europe 2015 in Munich!

We are now back in Berlin after three (intense) days at BIO-Europe 2015 in Munich. It was definitely a great fair. We covered the event with articles and videos to give you a live insight, (almost) as if you were there. Everything is below 😉 Day 1 : EU’s biggest Biotech Fair, BIO-Europe 2015, […]

November 5, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 4 Nov 2015

Last exclusive interview from #BIO-Europe 2015: Andre Hoekema, SVP Corporate Development of Galapagos

And here is the fourth interview I did at BIO-Europe 2015. This time, I am with Andre Hoekema, top-executive from the belgian Biotech success-story, Galapagos. We recently covered extensively the 400-employee company based north of Bruxelles. It made the biggest IPO ever by a EU Biotech on the NASDAQ, raising 270 million euros. It also recently had […]

November 4, 2015 - 1 minutemin - By Philip Hemme

News and Trends 4 Nov 2015

Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015

The Biotech industry relies a lot on partnering and deals. And 2015 has already been an active year. This was the theme of the second keynote conference from BIO-Europe 2015. It gathered four high-level speakers: The roundtable started with a summary of each companies’ activity in deals. Everyone has been busy, but Celgene seemed to […]

November 4, 2015 - 3 minutesmins - By Philip Hemme

peter Llewellyn Davies medigene interview

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

This is the third interview we publish from BIO (yes, we are working hard). It comes after the interview of Simon Moroney, CEO of MorphoSys and Jane Dancer, CBO of F-star. Medigene is another big/famous Biotech company of Munich, Germany. It was founded over 20 years ago and is now specialised in cell-based therapies. It counts […]

November 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview with F-star, a Cambridge-UK Immuno-oncology Biotech

Second interview of BIO-Europe 2015. This time, it’s a British company from Cambridge (UK): F-star. This morning we spoke with their CBO Jane Dancer. F-star is developing bi-specific antibodies for immuno-oncology and inflammatory disease. It has raised a total of 38 million euros from top EU VCs. Jane Dancer’s business tenure within the field is […]

November 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 3 Nov 2015

To IPO or not to IPO when you are a Biotech company? #BIO-Europe 2015

This is the second conference I attended at BIO-Europe. This is an interesting topic when you look at the different EU Biotech companies delaying their IPOs. The conference gathered four big speakers, among them Olivier Litzka, partner from Edmond de Rothschild (part of our TOP 15 EU VCs), Konrad Glund, the CEO of Berlin-based Probiodrug, […]

November 3, 2015 - 4 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Philip Hemme

About

Articles by Philip Hemme

Interview: CureVac, the ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market

EU’s Largest Private Biotech talking on the Future of mRNA Therapies

A Group of French Medics are Questioning the Fastest-Growing Big Biotech in the World…

This French Biotech has a ‘Super-Insulin’ up its Diabetes Sleeve

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

What Happened this Week? BIO-Europe 2015, mRNA deal, Cellectis CAR-T

Damn, that was BIO-Europe 2015 in Munich!

Last exclusive interview from #BIO-Europe 2015: Andre Hoekema, SVP Corporate Development of Galapagos

Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

Exclusive from BIO-Europe 2015: Interview with F-star, a Cambridge-UK Immuno-oncology Biotech

To IPO or not to IPO when you are a Biotech company? #BIO-Europe 2015

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Philip Hemme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!